Dividend grandma meets biotech casino in a US only stock rollercoaster
Report created on Aug 5, 2026Risk profile
5/7
Diversification profile
2/5
Positions
-
SC Schwab U.S. Dividend Equity ETF
SCHD - US8085247976 40.00% -
SC Schwab U.S. Large-Cap Growth ETF
SCHG - US8085243009 40.00% -
SC Schwab U.S. Small-Cap ETF
SCHA - US8085246077 10.00% -
AR Arrowhead Pharmaceuticals Inc
ARWR - US04280A1007 8.50% -
PR ProQR Therapeutics BV
PRQR - NL0010872495 1.50%
This portfolio looks like two different people built it and never spoke. On one side, 80% in broad, boring-ish Schwab ETFs, split evenly between dividend tilt and large-cap growth, plus a small-cap sprinkle. On the other, a nearly 10% YOLO bet on Arrowhead and a tiny lottery ticket in ProQR. Structurally, it’s a barbell: half “I like cash flows,” half “science might moon.” That kind of design means the core looks sensible at first glance, but the stock picks hijack the personality. Net result: a portfolio that pretends to be diversified but is really three funds and one very loud biotech shouting over everything.
Growth
Historically, this Franken-portfolio has actually crushed it: $1,000 turning into $4,928 is no joke, with a 17.38% CAGR versus 14.93% for the US market and 12.40% globally. Of course, it earned that the hard way — a max drawdown of -43.87% versus about -34% for the benchmarks. CAGR (Compound Annual Growth Rate) is your average speed; max drawdown is how deep the pothole felt on the worst part of the trip. Here, the ride’s been faster but also meaner, and recovery from the 2020 crater took seven months. Past data is yesterday’s weather: helpful, but it doesn’t swear to repeat the same storm pattern.
Projection
The Monte Carlo projection basically says: “Congrats, this might not blow up, but don’t expect past-decade magic.” Simulations put the median 15‑year outcome around $2,735 from $1,000, a lot lower than the historical rocket ship implied. Monte Carlo just reruns thousands of “what if” market paths using past volatility and relationships, then shows the spread of results. The likely band of $1,812–$4,202 is wide enough to remind that this isn’t a savings account. The scary part is the downside: a 5% chance of ending near $1,021 after 15 years, i.e., going nowhere after a decade and a half of drama.
Asset classes
- Stocks 100%
Asset classes: there is exactly one. Stocks, 100%. No bonds, no cash proxy, no real assets, nothing that behaves differently when markets have a tantrum. That’s fine if the goal is pure equity adrenaline, but let’s not pretend this is balanced. Asset allocation is basically your portfolio’s personality; here, the personality is “I only lift upper body and skip leg day forever.” When everything is in one asset class, crashes become full-contact events. There’s no shock absorber; the whole thing just rides the equity rollercoaster and hopes the seatbelt of diversification inside stocks is enough.
Sectors
- Technology 25%
- Health Care 24%
- Consumer Staples 9%
- Financials 9%
- Telecommunications 8%
- Consumer Discretionary 8%
- Industrials 7%
- Energy 7%
- Basic Materials 1%
- Real Estate 1%
Sector-wise, this is the “tech and healthcare are my entire personality” portfolio. Technology and health care together chew up roughly half of the exposure, with everything else getting table scraps. Dividend ETF plus large-cap growth plus a biotech side bet naturally lean into those areas, but the result is pretty lopsided. Sector allocation matters because different parts of the economy crash and recover on their own weird schedules. Here, the portfolio is basically betting that what worked in the last decade keeps working, with a particular obsession for innovation-heavy, regulation-sensitive land. If policy or sentiment turns, this stack feels it hard.
Regions
- North America 98%
- Europe Developed 2%
Geography: America or bust, apparently. With 98% in North America and a token 2% in developed Europe, this portfolio is basically saying the rest of the world is optional background noise. Geographic diversification is like not eating only one food group; other regions can zig when the home market zags. Here, everything depends on the US being the star forever. That’s worked brilliantly for a long time, but it also means any US-specific problem — policy shock, currency wobble, local recession — hits almost every part of this portfolio at once. “Global” is not a thing that’s really happening here.
Market capitalization
- Large-cap 47%
- Mega-cap 21%
- Mid-cap 18%
- Small-cap 9%
- Micro-cap 4%
The market cap mix looks fairly normal on the surface: mega and large caps dominate with 68% combined, mid caps at 18%, and small/micro around 13%. That’s roughly a scaled-up version of a broad equity index, not some extreme small-cap science experiment. But the presence of micro-cap and small-cap exposure, plus individual speculative biotech positions, subtly drags up risk. Market cap matters because big companies tend to be steadier ships, while small and micro caps are speedboats with questionable engines. This portfolio looks like a sensible cruise liner fleet with a few sketchy speedboats trying to pull fancy stunts in choppy water.
True holdings
-
-
AA Apple Inc. 4.25%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
NV NVIDIA Corporation 3.94%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
MS Microsoft Corporation 2.48%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
AM Amazon.com Inc 1.90%
Part of fund(s):- Schwab U.S. Large-Cap Growth ETF
-
AB Abbott Laboratories 1.88%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
AM Amgen Inc 1.74%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
MR Merck & Company Inc 1.73%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
KO The Coca-Cola Company 1.72%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
UN UnitedHealth Group Incorporated 1.69%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
- Top 10 total 29.83%
Look-through holdings reveal the usual suspects quietly running the show: Apple, NVIDIA, Microsoft, Amazon, plus big healthcare and defensive names like UnitedHealth and Coca‑Cola. Classic ETF ingredient list. The fun twist is that none of these are the real drama queen; Arrowhead sits alone at 8.5% with no ETF overlap, a single stock almost as important as the biggest mega-caps combined. Overlap analysis only covers ETF top‑10s, so actual duplication is higher than shown, but the theme is clear: there’s a hidden bet on Big Tech and Big Health, and then Arrowhead barges in as a concentrated, unhedged science project.
Factors
Factor exposures are estimated using statistical models based on historical data and measure systematic (market-relative) tilts, not absolute portfolio characteristics. Results may vary depending on the analysis period, data availability, and currency of the underlying assets.
Factor exposure is shockingly boring: everything is basically neutral — value, size, momentum, quality, yield, low volatility all hovering near 50%. Factor exposure is like checking the seasoning on a dish; here, it’s salt-and-pepper only, no aggressive spice. For a portfolio that looks chaotic at the security level, the underlying factor mix is almost eerily market-like. That means no strong lean into “cheap,” “fast-moving,” “stable,” or “high dividend” in aggregate; the big tilts are more about sectors and stock picking than systematic style. Someone either accidentally built a factor-balanced structure or randomness did a suspiciously clean job.
Risk contribution
-
Schwab U.S. Large-Cap Growth ETF
Weight: 40.00% 39.0% -
Schwab U.S. Dividend Equity ETF
Weight: 40.00% 28.4% -
Arrowhead Pharmaceuticals Inc
Weight: 8.50% 20.4% -
Schwab U.S. Small-Cap ETF
Weight: 10.00% 10.2% -
ProQR Therapeutics BV
Weight: 1.50% 2.0%
Risk contribution makes it clear who’s actually driving the mood swings. The large-cap growth ETF is 40% of the money and 39% of the risk — fair enough. The dividend ETF pulls its weight more gently: 40% of the money but only 28% of the risk. Then Arrowhead storms in at 8.5% weight and 20.4% of total risk, over 2.4x its fair share. That’s the classic “tiny friend who starts bar fights” holding. Risk contribution just measures which positions move the portfolio the most; here, three holdings account for almost 88% of the drama. This is concentration wearing a diversified ETF mask.
Risk vs. return
This chart shows the Efficient Frontier, calculated using your current assets with different allocation combinations. It highlights the best balance between risk and return based on historical data. "Efficient" portfolios maximize returns for a given risk or minimize risk for a given return. Portfolios below the curve are less efficient. This is informational and not a recommendation to buy or sell any assets.
Click on the colored dots to explore allocations.
On the efficient frontier chart, this portfolio actually behaves itself: it’s on or very near the frontier with a Sharpe ratio of 0.78, not far behind the max‑Sharpe version at 0.97. The efficient frontier is the curve showing the best possible return for each risk level using the existing ingredients, and being on it means the weights aren’t wildly inefficient. Sharpe ratio just compares return to volatility, like judging how much thrill you got per unit of nausea. Translation: given these specific holdings, the risk–return mix is reasonably well tuned. The chaos is in what’s owned, not how it’s sized overall.
Dividends
- Schwab U.S. Small-Cap ETF 1.00%
- Schwab U.S. Dividend Equity ETF 3.10%
- Schwab U.S. Large-Cap Growth ETF 0.40%
- Weighted yield (per year) 1.50%
For a portfolio with “Dividend Equity” as a 40% core piece, a total yield of 1.5% is underwhelming. That’s what happens when you bolt a high-yield sleeve onto a growth-heavy core and biotech moonshot — the income signal gets drowned out by capital-gain vibes and speculative noise. Dividend yield is just the annual cash paid out divided by price, like a paycheck on your invested salary. Here, the “income” story is mostly marketing; real life is more about price swings than steady checks. The dividend ETF is doing its job, but the rest of the gang clearly didn’t sign up for that storyline.
Ongoing product costs
- Schwab U.S. Small-Cap ETF 0.04%
- Schwab U.S. Dividend Equity ETF 0.06%
- Schwab U.S. Large-Cap Growth ETF 0.04%
- Weighted costs total (per year) 0.04%
Costs are the one area where this portfolio doesn’t sabotage itself. A total expense ratio around 0.04% is impressively low — basically couch-cushion money. TER (Total Expense Ratio) is the annual fee skimmed by the funds; here, Schwab’s ETFs are doing the budget airline thing without charging for oxygen. The irony is that the cheap wrapper is wrapped around a structurally bonkers mix of calm core and biotech chaos. So yes, fees are under control; you’re at least not overpaying to ride this particular rollercoaster. If anything looks smart here at first glance, it’s the cost line — probably the happiest number on the page.
What next?
Ready to invest in this portfolio?
Select a broker that fits your needs and watch for low fees to maximize your returns.
Create your own report?
Join our community!
Compare your holdings
How much do the funds you hold actually overlap with the ones people weigh them against?
The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.
Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.
Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.
Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.
By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.
Instrument logos provided by Elbstream.
Help us improve Insightfolio
Your feedback makes a difference! Share your thoughts in our quick survey. Take the survey